CDC vaccine advisory panel to weigh boosters’ necessity, J&J side effects
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will convene July 22 to discuss a pair of recent issues related to COVID-19 vaccines.
The agenda released ahead of the meeting includes discussion of the reported risk of Guillain-Barré Syndrome from the Johnson & Johnson vaccine, which recently prompted the Food and Drug Administration to update its vaccine recipient and vaccination provider fact sheets.
The committee will also discuss clinical considerations for additional vaccine doses in immunocompromised individuals; this represents the first formal consideration of boosters for individuals who have already completed a full dose regimen of the COVID-19 vaccines.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…